# Makoto Ohori

> Makoto Ohori is a Series A investor at UTokyo Innovation Platform backing Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [UTokyo Innovation Platform](https://shizune.co/investors/profile/utokyo-innovation-platform)
- Location: Tokyo, Japan
- Total investments: 5
- Last investment: Jul 2026
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/makoto-mark-ohori-ph-d-%E3%80%80-48611736

Makoto Ohori is a Partner and Chief Investment Officer at UTokyo Innovation Platform.Dr. Ohori received his Ph.D. in Pharmaceutical Sciences from the University of Tokyo, where his doctoral research focused on drug discovery and pharmacological evaluation of novel kinase inhibitors for autoimmune diseases. Dr. Ohori has collaborated withvarious institutions, such as Grenoble University Hospital, Kyoto University Hospital, Dokkyo University School of Medicine, Trevigen, Inc etc. He authored more than fifteen peer reviewed articles and invited reviews.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Biopharma | 3 | 60% |
| Medical | 2 | 40% |
| Life Science | 2 | 40% |
| Genetics | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Japan | 2 | 40% |
| United States | 2 | 40% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CORE Biomedicine | CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology. | $21M | Series A | Jul 28, 2026 |  |
| Libero Thera | LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo. | $1.3M | Venture - Series Unknown | Aug 01, 2024 |  |
| AceRNA Technologies | AceRNA contributes to regenerative medicine and drug discovery through the discovery of novel miRNA functions. It began operation in April 2018, with its headquarters in Kyoto in Japan. | $6.2M | Series B | May 07, 2024 |  |
| Vertero | Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $37.3M | Series C | Oct 13, 2021 |  |
| Libero Thera | LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo. | $4.9M | Venture - Series Unknown | May 14, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Longwood Fund](https://shizune.co/investors/profile/longwood-founders-fund) — VC Fund, 2 deals together
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund, 2 deals together
- [MP Healthcare Venture Management](https://shizune.co/investors/profile/mp-healthcare-venture-management-inc) — VC Fund, 2 deals together
- [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2) — VC Fund, 2 deals together
- [Autism Impact Fund](https://shizune.co/investors/profile/autism-impact-fund) — VC Fund, 1 deal together

## About UTokyo Innovation Platform

VC Fund · Tokyo, Japan

The University of Tokyo IPC is a company responsible for expanding the innovation ecosystem. Accelerate global innovation from the University of Tokyo through three activities: start-up support, investment business, and corporate innovation support.

5 contacts available at UTokyo Innovation Platform.

| Name | Title | Profile |
| --- | --- | --- |
| Makoto Ohori | Partner \| Chief Investment Officer, Life Science | https://shizune.co/investors/profile/makoto-ohori |
| Hiroho Fukuda | Auditor | https://shizune.co/investors/profile/hiroho-fukuda |
| Katsuhiko Oizumi | Founder, President and CEO | https://shizune.co/investors/profile/katsuhiko-oizumi |
| Kazuhiko Kakehi | Partner,Academic Co-Innovation | https://shizune.co/investors/profile/kazuhiko-kakehi |
| Kei Furukawa | Manager,Investment and Business Development | https://shizune.co/investors/profile/kei-furukawa |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Makoto Ohori invest in?

Makoto Ohori invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Makoto Ohori last invest?

The most recent investment recorded for Makoto Ohori closed in Jul 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co